XTX Topco Ltd Trims Holdings in Nevro Corp. (NYSE:NVRO)

XTX Topco Ltd trimmed its position in Nevro Corp. (NYSE:NVRO) by 32.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,608 shares of the medical equipment provider’s stock after selling 8,103 shares during the quarter. XTX Topco Ltd’s holdings in Nevro were worth $93,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of NVRO. Western Standard LLC purchased a new stake in shares of Nevro in the 3rd quarter valued at $5,473,000. Jacobs Levy Equity Management Inc. boosted its holdings in Nevro by 50.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 732,717 shares of the medical equipment provider’s stock valued at $4,096,000 after purchasing an additional 246,979 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its position in Nevro by 2.4% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 4,391,258 shares of the medical equipment provider’s stock worth $24,547,000 after purchasing an additional 102,150 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Nevro by 7,506.2% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 17,114 shares of the medical equipment provider’s stock valued at $96,000 after buying an additional 16,889 shares during the last quarter. Finally, PDT Partners LLC acquired a new position in shares of Nevro in the 3rd quarter valued at about $99,000. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Analysts Set New Price Targets

NVRO has been the topic of several analyst reports. Citigroup dropped their target price on Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. JMP Securities reaffirmed a “market perform” rating on shares of Nevro in a research note on Tuesday, November 12th. Truist Financial decreased their target price on shares of Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research note on Wednesday. StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group cut their price objective on shares of Nevro from $7.00 to $4.00 and set a “hold” rating for the company in a report on Monday, December 9th. Three analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.30.

Nevro Trading Up 5.6 %

NVRO stock opened at $3.79 on Friday. Nevro Corp. has a 12-month low of $3.52 and a 12-month high of $22.52. The business’s 50-day moving average is $4.66 and its 200 day moving average is $6.29. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. The stock has a market cap of $142.02 million, a price-to-earnings ratio of -2.01 and a beta of 0.84.

Nevro (NYSE:NVRO) last issued its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The firm had revenue of $96.60 million for the quarter, compared to analyst estimates of $93.09 million. During the same period in the previous year, the company posted ($0.65) earnings per share. The business’s revenue was down 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Nevro Corp. will post -2.43 EPS for the current fiscal year.

Nevro Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.